Resumen
Objetivo: Analizar la asociación entre la disbiosis intestinal y las enfermedades autoinmunes, destacando los mecanismos inmunológicos y las implicaciones terapéuticas. Revisión bibliográfica: Esta es una revisión narrativa que aborda la composición y función de la microbiota, así como los factores asociados a la disbiosis. El desequilibrio microbiano compromete la barrera intestinal, favorece la translocación bacteriana y promueve la inflamación sistémica de bajo grado. Se discuten mecanismos como la activación de las células presentadoras de antígenos, la polarización Th1/Th17, la reducción de las células T reguladoras, la producción de citocinas proinflamatorias y el mimetismo molecular, relacionando estos procesos con la progresión del lupus eritematoso, la artritis reumatoide y la diabetes mellitus tipo 1. También se analizan estrategias terapéuticas basadas en la modulación de la microbiota, incluyendo probióticos, prebióticos, intervenciones dietéticas y trasplante de microbiota. Consideraciones finales: Los hallazgos indican que la microbiota intestinal es esencial para la homeostasis inmunológica, siendo la disbiosis un determinante de la inflamación crónica. Las intervenciones basadas en el microbioma muestran potencial terapéutico, a pesar de las limitaciones relacionadas con la variabilidad individual y la ausencia de protocolos estandarizados.
Referencias
ADAWI M. The role of gut microbiota in autoimmune disease progression and therapy: a comprehensive synthesis. Frontiers in Microbiomes, 2025; 4: 1553243.
ALI AY. Gut microbiota dysbiosis and associated immune response in systemic erythematosus: impact of disease and treatment. Gut Pathogens, 2025; 17: 10.
BUENO IB, et al. O papel da microbiota intestinal na patogênese das doenças autoimunes. Revista Ibero-Americana de Humanidades, Ciências e Educação, 2024; 8(15): 574.
CHEN Y, et al. A microbiota: a crucial mediator in gut homeostasis and colonization resistance. Frontiers in Microbiology, 2024; 15: 1417864.
CHRISTOVICH A, LUO XM. Gut microbiota, leaky gut, and autoimmune diseases. Frontiers in Immunology, 2022; 13: 946248.
DE OLIVEIRA GLV, et al. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology, 2017; 152(1): 1–12.
DU L, et al. Rifaximin alleviates intestinal barrier disruption and systemic inflammation via the PXR/NF-κB/MLCK pathway. International Immunopharmacology, 2024; 143: 113462.
FRIAS J, et al. Rifaximin as a therapeutic ally in the modulation of dysbiosis: a narrative review of its applicability in gastrointestinal disorders. GE Portuguese Journal of Gastroenterology, 2025; 32(6): 423–437.
IVASHKIN V, et al. Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study. BMC Gastroenterology, 2023; 23(1): 82.
JACÓ AP. Impacto da microbiota intestinal na regulação imunológica: mecanismos de interação e consequências da disbiose. Revista Brasileira de Educação e Saúde, 2024; 15(1): 11195.
KOH A, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell, 2016; 165(6): 1332–1345.
LEI J, et al. Intestinal microbiota dysbiosis in acute kidney injury: novel insights into mechanisms and promising therapeutic strategies. Renal Failure, 2022; 44: 571–583.
LI G, XIONG Y. Gut microbiota-derived metabolites modulate Treg/Th17 balance: novel therapeutic targets in autoimmune diseases. Frontiers in Immunology, 2025; 16: 1701733.
LI Y, et al. Therapeutic modulation of gut microbiota in autoimmune diseases: current evidence and future perspectives. Frontiers in Immunology, 2024; 15: 1298476.
LIMA AER. Intestinal dysbiosis and the relationship with autoimmune diseases. Journal of Autoimmune Research, 2023; 15: 1–12.
LYNN DJ, et al. Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nature Reviews Immunology, 2021; 21: 1–15.
OMAR A. Engineering the microbiome: a novel approach to managing autoimmune diseases. NeuroMolecular Medicine, 2025; 27: 1–15.
OPAZO MC. Intestinal microbiota influences non-intestinal related autoimmune diseases. Frontiers in Immunology, 2018; 9: 1–10.
OLIVEIRA GLV. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Autoimmunity Reviews, 2017; 16: 117–126.
PEREIRA ALS. O impacto da disbiose intestinal na saúde metabólica e imunológica. Revista Eletrônica de Educação e Saúde, 2024; 11: 251–259.
PONZIANI FR, et al. Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation. World Journal of Gastroenterology, 2017; 23(25): 4491–4499.
SHAHEEN WA. Gut microbiome and autoimmune disorders. International Journal of Molecular Sciences, 2022; 23: 1–22.
SHEN Q, et al. Emerging role of gut microbiota in autoimmune diseases. Frontiers in Immunology, 2025; 16: 1386249.
SMOLINSKA S, et al. A review of the influence of prebiotics, probiotics, synbiotics, and postbiotics on the human gut microbiome and intestinal integrity. Journal of Clinical Medicine, 2025; 14(11): 3673.
WANG X, et al. Emerging role of gut microbiota in autoimmune diseases. Frontiers in Immunology, 2024; 15: 1365554.
ZENG L, et al. Efficacy and safety of gut microbiota-based therapies: a review and meta-analysis of 80 randomized controlled trials. Gut Microbes, 2024; 15: 2309473.
ZHENG D, et al. Interaction between microbiota and immunity in health and disease. Cell Research, 2020; 30: 492-506.
